Compare SBCF & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBCF | NUVB |
|---|---|---|
| Founded | 1926 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.9B |
| IPO Year | N/A | N/A |
| Metric | SBCF | NUVB |
|---|---|---|
| Price | $33.90 | $5.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $31.00 | $10.44 |
| AVG Volume (30 Days) | 729.0K | ★ 6.3M |
| Earning Date | 01-29-2026 | 03-05-2026 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | ★ 23.57 | N/A |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $556,541,000.00 | $26,748,000.00 |
| Revenue This Year | $33.11 | $616.63 |
| Revenue Next Year | $29.90 | $202.59 |
| P/E Ratio | $20.14 | ★ N/A |
| Revenue Growth | 12.63 | ★ 1137.19 |
| 52 Week Low | $21.36 | $1.54 |
| 52 Week High | $34.14 | $9.75 |
| Indicator | SBCF | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 64.71 | 27.65 |
| Support Level | $32.00 | $6.07 |
| Resistance Level | $33.57 | $6.63 |
| Average True Range (ATR) | 0.86 | 0.53 |
| MACD | 0.13 | -0.42 |
| Stochastic Oscillator | 90.45 | 1.79 |
Seacoast Banking Corp of Florida is a holding company for Seacoast National Bank. The company provides integrated financial services including commercial and consumer banking, wealth management, and mortgage and insurance services to customers across Florida, and through mobile and online banking solutions. In addition, it provides services such as treasury management, brokerage and credit facilities.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.